Dr. Stephane Angers

Donnelly Centre for Cellular + Biomolecular Research
Department of Biochemistry, Faculty of Medicine
Dept. of Pharmaceutical Sciences, Faculty of Pharmacy
University of Toronto

phone: (416) 453-1312
email: stephane.angers@utoronto.ca
lab website: www.angerslab.org

ACADEMIC DEGREES AND APPOINTMENTS:

Sept 2021-	Director, Donnelly Centre for Cellular + Biomolecular Research University of Toronto www.thedonnellycentre.utoronto.ca
2019-2021	Founding Co-Director PRiME – Precision Medicine Strategic Initiative at the University of Toronto https://www.prime.utoronto.ca
July 2017-	Professor Leslie Dan Faculty of Pharmacy, Department of Pharmaceutical Sciences Department of Biochemistry, University of Toronto University of Toronto
2015-2021	Associate Dean of Research Leslie Dan Faculty of Pharmacy, University of Toronto
2012-2017	Associate Professor Leslie Dan Faculty of Pharmacy, Department of Pharmaceutical Sciences Department of Biochemistry, University of Toronto University of Toronto
2013-2015	Graduate Coordinator Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy
2006-2012	Assistant Professor Leslie Dan Faculty of Pharmacy, Department of Pharmaceutical Sciences Department of Biochemistry, University of Toronto University of Toronto
2002-2006	Post-doctoral Fellow, Howard Hughes Medical Institute University of Washington, Seattle Supervisor: Dr. Randall T. Moon
1998-2002	Ph.D, Biochemistry Université de Montréal Montréal, Qc Thesis supervisor: Dr. Michel Bouvier
1993- 1997	B. Sc. Biochemistry McGill University Montréal, Qc

AWARDS AND RECOGNITIONS

2021- Charles H. Best Chair in Medical Research

2007-2017 Canada Research Chair in Functional Architecture of Signal Transduction

INNOVATION AND STARTUP CREATION

2019 Scientific Founder AntlerA Therapeutics (acquired by Roche in July 2024)
Toronto, On, Canada

2018 Scientific Founder ModMab Therapeutics
Foster City, CA, USA

Patents.

id	title	inventor/author	status
US14/911,983	Antibodies against frizzled proteins and methods of use thereof	Stephane ANGERS, Amandeep GAKHAL, Jason MOFFAT, Guohua Pan, Melanie ROBITAILLE, Sachdev Sidhu	Granted 2018-09-18
US17/176,155	Frizzled5 protein-binding agents	Guohua Pan, Jason Moffat, Sachdev Sidhu, Stephane Angers, Zachary Steinhart, Xiaowei Wang	Filed 2021-02-15
PCT/IB2019/051174	Multivalent binding molecules activating wnt signaling and uses thereof	Yuyong TAO, Stephane ANGERS, Sachdev Sidhu	Filed 2019-02-14, Status Pending
WO-2020010471-A1	Microfluidic devices and methods of use	Shana Olwyn KELLEY, Edward Sargent, David PHILPOTT, Peter ALDRIDGE, Stephane ANGERS, Jason MOFFAT, Barbara MAIR, Sanna MASUD	2020-01-16
PCT/IB2020/055463	Multivalent fzd and wnt binding molecules and uses thereof	Stephane ANGERS, Sachdev Sidhu, Yuyong TAO	Filed 2020-06-10
PCT/CA2020/051119	Antibodies that bind to lrp5 proteins and methods of use	Sachdev S. Sidhu, Guohua Pan, Nish PATEL, Jason MOFFAT, Stephane ANGERS, Jarrett ADAMS, Jagath R. Junutula	Filed 2020-08-14
US18/501,589	Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof	Stephane ANGERS, Sachdev Sidhu, Levi BLAZER, Jarrett ADAMS, Somasekar Seshagiri	Filed 2023-11-03, status Pending

PCT/CA2020/051103	Frizzled receptor antibodies and uses thereof	Jarrett ADAMS, Stephane ANGERS, Amandeep GAKHAL, Jason MOFFAT, Guohua Pan, Zvezdan PAVLOVIC, Sachdev Sidhu, Zachary STEINHART	Filed 2017-01-27, Status Pending
WO-2021108927-A1	Methods and compositions for treating cancers having f-box and wd-repeat protein 7 (fbxw7) alterations and/or cyclin l1 (ccnl1) gain or amplification	Stephane ANGERS, Zachary STEINHART, Siobhan O'brien	2021-06-10
PCT/CA2020/051120	Antibodies that bind to LRP6 proteins and methods of use	Jarrett ADAMS, Stephane ANGERS, Jagath R. Junutula, Jason MOFFAT, Guohua Pan, Nish PATEL, Sachdev Sidhu	Filed 2020-08-14

SCIENTIFIC COMMUNICATIONS

Published peer-reviewed papers (Cited >21,800 citations)

1- Targeting synthetic lethality between non-homologous end joining and radiation in very-high-risk medulloblastoma.
DeCarlo A, MacLeod G, Fernandes da Silva C, Shen LQ, Povilaikaite J, Deane M, Aragao L, Sie M, Termini D, Magee J, Gudenas B, Sukumaran S, Charron F, Marcellus R, Al-Awar R, Aman A, Reynaud D, Trolat A, Wybenga-Groot L, Tabori U, Nör C, Harding SM, Moran MF, Northcott PA, Dirks P, Angers S, Ramaswamy V.Cell Rep Med. 2025 Jul 15;6(7):102202.

2- Targeting the Dependence on PIK3C3-mTORC1 Signaling in Dormancy-Prone Breast Cancer Cells Blunts Metastasis Initiation.
Elkholi IE, Robert A, Malouf C, Wu JL, Kuasne H, Drapela S, Macleod G, Hébert S, Pacis A, Calderon V, Kleinman CL, Gomes AP, Alvarez JV, Aguirre-Ghiso JA, Park M, Angers S, Côté JF.Cancer Res. 2025 May 15:OF1-OF20

3- PRMT5 promotes full-length HTT expression by repressing multiple proximal intronic polyadenylation sites.
Yadav M, AlQazzaz MA, Ciamponi FE, Ho JC, Maron MI, Sababi AM, MacLeod G, Ahmadi M, Bullivant G, Tano V, Langley SR, Sánchez-Osuna M, Sachamitr P, Kushida M, Bardile CF, Pouladi MA, Kurtz R, Richards L, Pugh T, Tyers M, Angers S, Dirks PB, Bader GD, Truant R, Massirer KB, Barsyte-Lovejoy D, Shechter D, Harding RJ, Arrowsmith CH, Prinos P.
Nucleic Acids Res. 2025 Apr 22;53(8)

4- Mechanistic insights into Wnt-β-catenin pathway activation and signal transduction.
Maurice MM, Angers S.
Nat Rev Mol Cell Biol. 2025 May;26(5):371-388

5- Selective activation of FZD2 and FZD7 reveals non-redundant function during mesoderm differentiation.
Chidiac R, Yang A, Kubarakos E, Mikolajewicz N, Han H, Almeida MP, Thibeault PE, Lin S, MacLeod G, Gratton JP, Moffat J, Angers S.
Stem Cell Reports. 2025 Feb 11;20(2):102391

6- mRNA decay pre-complex assembly drives timely cell-state transitions during differentiation.
Komori H, Rastogi G, Bugay JP, Luo H, Lin S, Angers S, Smibert CA, Lipshitz HD, Lee CY.
Cell Rep. 2025 Jan 28;44(1):115138

7- The WAVE regulatory complex interacts with Boc and is required for Shh-mediated axon guidance.
Balekoglu N, Michaud JF, Sauvé R, Ayinde KS, Lin S, Liu Y, Kramer DA, Zhang K, Steffen A, Stradal T, Angers S, Chen B, Yam PT, Charron F.
iScience. 2024 Nov 6;27(12):111333

8- Identification of VISTA regulators in macrophages mediating cancer cell survival.
Abdrabou AM, Ahmed SU, Fan MJ, Duong BTV, Chen K, Lo PY, Mayes JM, Esmaeili F, GhavamiNejad A, Zargartalebi H, Atwal RS, Lin S, Angers S, Kelley SO.
Sci Adv. 2024 Nov 29;10(48)

9- TMCO1 is upregulated in breast cancer and regulates the response to pro-apoptotic agents in breast cancer cells.
Bong AHL, Robitaille M, Lin S, McCart-Reed A, Milevskiy M, Angers S, Roberts-Thomson SJ, Monteith GR.
Cell Death Discov. 2024 Oct 1;10(1):421. doi: 10.1038/s41420-024-02183-0.

10- Fitness Screens Map State-Specific Glioblastoma Stem Cell Vulnerabilities.
MacLeod G, Molaei F, Haider S, Almeida MP, Lin S, Kushida M, Sureshkumar H, Bhatti JK, Lu JQ, Schramek D, Dirks PB, Angers S.
Cancer Res. 2024 Aug 26. doi: 10.1158/0008-5472.CAN-23-4024. Online ahead of print.

11- Get your receptors in a knot with new Wnt signaling agonists.
Wolf L, Angers S.
Cell Chem Biol. 2024 Jun 20;31(6):1044-1046. doi: 10.1016/j.chembiol.2024.05.010.

12- ZO-1 interacts with YB-1 in endothelial cells to regulate stress granule formation during angiogenesis.
El Bakkouri Y, Chidiac R, Delisle C, Corriveau J, Cagnone G, Gaonac'h-Lovejoy V, Chin A, Lécuyer É, Angers S, Joyal JS, Topisirovic I, Hulea L, Dubrac A, Gratton JP.
Nat Commun. 2024 May 23;15(1):4405. doi: 10.1038/s41467-024-48852-7.

13- Phenotypic targeting using magnetic nanoparticles for rapid characterization of cellular proliferation regulators.
Wang Z, Wang H, Lin S, Angers S, Sargent EH, Kelley SO.
Sci Adv. 2024 May 10;10(19):eadj1468. doi: 10.1126/sciadv.adj1468. Epub 2024 May 8.

14- Exploiting spatiotemporal regulation of FZD5 during neural patterning for efficient ventral midbrain specification.
Yang A, Chidiac R, Russo E, Steenland H, Pauli Q, Bonin R, Blazer LL, Adams JJ, Sidhu SS, Goeva A, Salahpour A, Angers S
Development. 2024 Mar 1;151(5):

15- The CDK12 inhibitor SR-4835 functions as a molecular glue that promotes cyclin K degradation in melanoma.
Houles T, Boucher J, Lavoie G, MacLeod G, Lin S, Angers S, Roux PP.
Cell Death Discov. 2023 Dec 16;9(1):459. doi: 10.1038/s41420-023-01754-x.

16- CRISPR Screening in Tandem with Targeted mtDNA Damage Reveals WRNIP1 Essentiality.
Sack T, Dhavarasa P, Szames D, O'Brien S, Angers S, Kelley SO.
ACS Chem Biol. 2023 Dec 15;18(12):2599-2609.

17- FBXW7-loss Sensitizes Cells to ATR Inhibition Through Induced Mitotic Catastrophe.
O'Brien S, Ubhi T, Wolf L, Gandhi K, Lin S, Chaudary N, Dhani NC, Milosevic M, Brown GW, Angers S.
Cancer Res Commun. 2023 Dec 21;3(12):2596-2607

18- Identification of druggable regulators of cell secretion via a kinome-wide screen and high-throughput immunomagnetic cell sorting.
Labib M, Wang Z, Kim Y, Lin S, Abdrabou, Yousefi H, Lo PY, Angers S, Sargent EH, Kelley SO.
Nat Biomed Eng. 2023 Nov 27.

19- A Frizzled4-LRP5 agonist promotes blood-retina barrier function by inducing a Norrin-like transcriptional response.
Zhang L, Abedin M, Jo HN, Levey J, Dinh QC, Chen Z, Angers S, Junge HJ.
iScience. 2023 Jul 18;26(8):107415

20- Relative Biological Effectiveness (RBE) of [^{64}Cu]Cu and [^{177}Lu]Lu-NOTA-panitumumab F $(ab')_2$ radioimmunotherapeutic agents vs. γ-radiation for decreasing the clonogenic survival in vitro of human pancreatic ductal adenocarcinoma (PDAC) cells.
Boyle AJ, Cai Z, O'Brien S, Crick J, Angers S, Reilly RM.
Nucl Med Biol. 2023 Jul-Aug;122-123:108367

21- Targeted alveolar regeneration with Frizzled-specific agonists.
Nabhan AN, Webster JD, Adams JJ, Blazer L, Everrett C, Eidenschenk C, Arlantico A, Fleming I, Brightbill HD, Wolters PJ, Modrusan Z, Seshagiri S, Angers S, Sidhu SS, Newton K, Arron JR, Dixit VM.
Cell. 2023 Jul 6;186(14):2995-3012.e15.

22- Pyruvate Kinase M (PKM) binds ribosomes in a poly-ADP ribosylation dependent manner to induce translational stalling.
Kejiou NS, Ilan L, Aigner S, Luo E, Tonn T, Ozadam H, Lee M, Cole GB, Rabano I, Rajakulendran N, Yee BA, Najafabadi HS, Moraes TF, Angers S, Yeo GW, Cenik C, Palazzo AF.
Nucleic Acids Res. 2023 May 24

23- Modulation of Wnt-β-catenin signaling with antibodies: therapeutic opportunities and challenges.
O'Brien S, Chidiac R, Angers S.
Trends Pharmacol Sci. 2023 Jun;44(6):354-365

24- Efficient Delivery of Biological Cargos into Primary Cells by Electrodeposited Nanoneedles via Cell-Cycle-Dependent Endocytosis.
Wang Z, Wang H, Lin S, Labib M, Ahmed S, Das J, Angers S, Sargent EH, Kelley SO.
Nano Lett. 2023 Apr 11.

25- Mechanical nanosurgery of chemoresistant glioblastoma using magnetically controlled carbon nanotubes.
Wang X, Gong Z, Wang T, Law J, Chen X, Wanggou S, Wang J, Ying B, Francisco M, Dong W, Xiong Y, Fan JJ, MacLeod G, Angers S, Li X, Dirks PB, Liu X, Huang X, Sun Y.
Sci Adv. 2023 Mar 29;9(13)

26- Wnt signaling in stem cells during development and cell lineage specification.
Chidiac R, Angers S.
Curr Top Dev Biol. 2023;153:121-143

27- nuPRISM: Microfluidic Genome-Wide Phenotypic Screening Platform for Cellular Nuclei.
Abdrabou AM, Duong BTV, Chen K, Atwal RS, Labib M, Lin S, Angers S, Kelley SO.
ACS Cent Sci. 2022 Dec 28;8(12):1618-1626

28- Crystal structure of the CDK11 kinase domain bound to the small-molecule inhibitor OTS964.
Kelso S, O'Brien S, Kurinov I, Angers S, Sicheri F.
Structure. 2022 Oct 24

29- CDK12 is hyperactivated and a synthetic-lethal target in BRAF-mutated melanoma.
Houles T, Lavoie G, Nourreddine S, Cheung W, Vaillancourt-Jean É, Guérin CM, Bouttier M, Grondin B, Lin S, Saba-El-Leil MK, Angers S, Meloche S, Roux PP.
Nat Commun. 2022 Oct 29;13(1):6457

30- SCFFBXW7 regulates G2-M progression through control of CCNL1 ubiquitination.
O'Brien S, Kelso S, Steinhart Z, Orlicky S, Mis M, Kim Y, Lin S, Sicheri F, Angers S.
EMBO Rep. 2022 Oct 24

31- Single-cell spatial transcriptomics reveals a dynamic control of metabolic zonation and liver regeneration by endothelial cell Wnt2 and Wnt9b.
Hu S, Liu S, Bian Y, Poddar M, Singh S, Cao C, McGaughey J, Bell A, Blazer LL, Adams JJ, Sidhu SS, Angers S, Monga SP.
Cell Rep Med. 2022 Oct 18;3(10)

32- Genome-wide in vivo screen of circulating tumor cells identifies SLIT2 as a regulator of metastasis.
Xia F, Ma Y, Chen K, Duong B, Ahmed S, Atwal R, Philpott D, Ketela T, Pantea J, Lin S, Angers S, Kelley SO.
Sci Adv. 2022 Sep 2;8(35)

33- Frizzled does not get bent out of shape by Wnt.
Angers S.
Sci Signal. 2022 Aug 23;15(748)

34- Identification of Drug Resistance Mechanisms Using Genome-Wide CRISPR-Cas9 Screens.
MacLeod G, Rajakulendran N, Angers S.
Methods Mol Biol. 2022;2535:141-156

35- Nanoparticle Amplification Labeling for High-Performance Magnetic Cell Sorting.
Wang Z, Wang H, Lin S, Ahmed S, Angers S, Sargent EH, Kelley SO.
Nano Lett. 2022 Jun 22;22(12):4774-4783

36- Rapid On-Cell Selection of High-Performance Human Antibodies.
Philpott DN, Gomis S, Wang H, Atwal R, Kelil A, Sack T, Morningstar B, Burnie C, Sargent EH, Angers S, Sidhu S, Kelley SO.
ACS Cent Sci. 2022 Jan 26;8(1):102-109

37- The F-box protein Bard (CG14317) targets the Smaug RNA-binding protein for destruction during the Drosophila maternal-to-zygotic transition.
Cao WX, Karaiskakis A, Lin S, Angers S, Lipshitz HD.
Genetics. 2022 Jan 4;220(1)

38- A Norrin/Wnt surrogate antibody stimulates endothelial cell barrier function and rescues retinopathy.
R. Chidiac , Md. Abedin , G. Macleod , A. Yang , P.Thibault , L. Blazer , J. Adams , L. Zhang , H. Roehrich , H. Jo , S. Seshagiri , S. Sidhu , H. Junge, S. Angers
EMBO Mol Med. 2021

39- Wnt signaling inhibition confers induced synthetic lethality to PARP inhibitors.

Angers S.
EMBO Mol Med. 2021 Apr 9;13(4):e14002.

40- The RanBP2/RanGAP1-SUMO complex gates β-arrestin2 nuclear entry to regulate the Mdm2-p53 signaling axis.
Blondel-Tepaz E, Leverve M, Sokrat B, Paradis JS, Kosic M, Saha K, Auffray C, Lima-Fernandes E, Zamborlini A, Poupon A, Gaboury L, Findlay J, Baillie GS, Enslen H, Bouvier M, Angers S, Marullo S, Scott MGH.
Oncogene. 2021 Mar;40(12):2243-2257.

41- Single-cell chromatin accessibility profiling of glioblastoma identifies an Invasive cancer stem cell population associated with lower survival.
Guilhamon P, Chesnelong C, Kushida MM, Nikolic A, Singhal D, MacLeod G, Madani Tonekaboni SA, Cavalli FM, Arlidge C, Rajakulendran N, Rastegar N, Hao X, Hassam R, Smith LJ, Whetstone H, Coutinho FJ, Nadorp B, Ellestad KI, Luchman AH, Chan JA, Shoichet MS, Taylor MD, Haibe-Kains B, Weiss S, Angers S, Gallo M, Dirks PB, Lupien M.
Elife. 2021 Jan 11;10:e64090.

42- Gradient of developmental and injury-response transcriptional states defines functional vulnerabilities underpinning glioblastoma heterogeneity.
LM Richards, O.K.N. Whitley, G MacLeod, F.M.G. Cavalli, FJ. Coutinho, JE. Jaramillo, N. Svergun, M. Riverin, DC. Croucher, M, Kushida, K. Yu, P.Guilhamon, N. Rastegar, M. Ahmadi, JK. Bhatti, DA. Bozek, N. Li, L. Lee, C.Che, E. Luis, NI. Park, Z. Xu, T. Ketela, RA. Moore, MA. Marra, J.Spears, MD. Cusimano, S. Das, M. Bernstein, B. Haibe-Kains, M. Lupien, H. A. Luchman, S.Weiss, S.Angers, P.B. Dirks, GD. Bader, TJ. Pugh
Nature Cancer, October 2020

43- Copper bioavailability is a KRAS-specific vulnerability in colorectal cancer.
Aubert L, Nandagopal N, Steinhart Z, Lavoie G, Nourreddine S, Berman J, Saba-El-Leil MK, Papadopoli D, Lin S, Hart T, Macleod G, Topisirovic I, Gaboury L, Fahrni CJ, Schramek D, Meloche S,Angers S, Roux PP.
Nat Commun. 2020 Jul 24;11(1):3701.

44- Single-molecule dynamics of Dishevelled at the plasma membrane and Wnt pathway activation.
Ma W, Chen M, Kang H, Steinhart Z, Angers S, He X, Kirschner MW.
Proc Natl Acad Sci U S A. 2020 Jul 14;117(28):16690-16701.

45- Precise Temporal Regulation of Post-transcriptional Repressors Is Required for an Orderly Drosophila Maternal-to-Zygotic Transition.
Cao WX, Kabelitz S, Gupta M, Yeung E, Lin S, Rammelt C, Ihling C, Pekovic F, Low TCH, Siddiqui NU, Cheng MHK, Angers S, Smibert CA, Wühr M, Wahle E, Lipshitz HD.
Cell Rep. 2020 Jun 23;31(12):107783.

46- Metabolic Regulation of the Epigenome Drives Lethal Infantile Ependymoma.
Michealraj KA, Kumar SA, Kim LJY, Cavalli FMG, Przelicki D, Wojcik JB, Delaidelli A, Bajic A, Saulnier O, MacLeod G, Vellanki RN, Vladoiu MC, Guilhamon P, Ong W, Lee JJY, Jiang Y, Holgado BL, Rasnitsyn A, Malik AA, Tsai R, Richman CM, Juraschka K, Haapasalo J, Wang EY, De Antonellis P, Suzuki H, Farooq H, Balin P, Kharas K, Van Ommeren R, Sirbu O, Rastan A, Krumholtz SL, Ly M, Ahmadi M, Deblois G, Srikanthan D, Luu B, Loukides J, Wu X, Garzia L, Ramaswamy V, Kanshin E, Sánchez-Osuna M, El-Hamamy I, Coutinho FJ, Prinos P, Singh S, Donovan LK, Daniels C, Schramek D, Tyers M, Weiss S, Stein LD, Lupien M, Wouters BG, Garcia BA, Arrowsmith CH, Sorensen PH,Angers S, Jabado N, Dirks PB, Mack SC, Agnihotri S, Rich JN, Taylor MD.
Cell. 2020 Jun 11;181(6):1329-1345.e24.

47- Nanostructured Architectures Promote the Mesenchymal-Epithelial Transition for Invasive Cells.

Wang Z, Xia F, Labib M, Ahmadi M, Chen H, Das J, Ahmed S, Angers S, Sargent EH, Kelley SO.
ACS Nano. 2020 May 26;14(5):5324-5336.

48- The RNA-Binding Protein Rasputin/G3BP Enhances the Stability and Translation of Its Target mRNAs.
Laver JD, Ly J, Winn AK, Karaiskakis A, Lin S, Nie K, Benic G, Jaberi-Lashkari N, Cao WX, Khademi A, Westwood JT, Sidhu SS, Morris Q, Angers S, Smibert CA, Lipshitz HD.
Cell Rep. 2020 Mar 10;30(10):3353-3367.e7.

49- IPO11 mediates bcatenin nuclear import in a subset of colorectal cancers
Mis M, O'Brien S, Steinhart Z, Lin S, Hart T, Moffat J, Angers S
J Cell Biol, 219 (2) 2020 Feb 3

50- Functional Enhancers Shape Extrachromosomal Oncogene Amplifications.
Morton AR, Dogan-Artun N, Faber ZJ, MacLeod G, Bartels CF, Piazza MS, Allan KC, Mack SC, Wang X, Gimple RC, Wu Q, Rubin BP, Shetty S, Angers S, Dirks PB, Sallari RC, Lupien M, Rich JN, Scacheri PC.
Cell. 2019 Nov 27;179(6):1330-1341.e13. 2019 Nov 21.

51- High-throughput genome-wide phenotypic screening via immunomagnetic cell sorting.
Mair B, Aldridge PM, Atwal RS, Philpott D, Zhang M, Masud SN, Labib M, Tong AHY, Sargent EH, Angers S, Moffat J, Kelley SO.
Nat Biomed Eng. 2019 Oct;3(10):796-805.

52- Tailored tetravalent antibodies potently and specifically activate Wnt/Frizzled pathways in cells, organoids and mice
Yuyong Tao , Monika Mis , Levi Blazer , Mart Ustav , Zachary Steinhart , Rony Chidiac , Elli Kubarakos , Siobhan O'Brien , Xiaomei Wang , Nick Jarvik , Nish Patel , Jarrett Adams , Jason Moffat , Stephane Angers and Sachdev Sidhu
eLife, 2019 2019 Aug 27;8:e46134.

53- Identifying chemogenetic interactions from CRISPR screens with drugZ.
Colic M, Wang G, Zimmermann M, Mascall K, McLaughlin M, Bertolet L, Lenoir WF, Moffat J, Angers S, Durocher D, Hart T.
Genome Med. 2019 Aug 22;11(1):52. doi: 10.1186/s13073-019-0665-3.

54- Genome-Wide CRISPR-Cas9 Screens Expose Genetic Vulnerabilities and Mechanisms of Temozolomide Sensitivity in Glioblastoma Stem Cells.
MacLeod G, Bozek DA, Rajakulendran N, Monteiro V, Ahmadi M, Steinhart Z, Kushida MM, Yu H, Coutinho F, Cavalli FMG, Restall I, Hao X, Hart T, Luchman HA, Weiss S, Dirks PB, Angers S.
Cell Rep. 2019 Apr 16;27(3):971-986.e9. doi: 10.1016/j.celrep.2019.03.047

55- Structure-guided design fine-tunes pharmacokinetics, tolerability, and antitumor profile of multispecific frizzled antibodies.
Raman S, Beilschmidt M, To M, Lin K, Lui F, Jmeian Y, Ng M, Fernandez M, Fu Y, Mascall K, Duque A, Wang X, Pan G, Angers S, Moffat J, Sidhu SS, Magram J, Sinclair AM, Fransson J, Julien JP.
Proc Natl Acad Sci U S A. 2019 Apr 2;116(14):6812-6817.

56- Wnt and Notch signaling govern self-renewal and differentiation in a subset of human glioblastoma stem cells.
Rajakulendran N, Rowland KJ, Selvadurai HJ, Ahmadi M, Park NI, Naumenko S, Dolma S, Ward RJ, So M, Lee L, MacLeod G, Pasiliao C, Brandon C, Clarke ID, Cusimano MD, Bernstein M, Batada N, Angers S, Dirks PB.
Genes Dev. 2019 May 1;33(9-10):498-510.

57- Agonist-induced desensitisation of β3 -adrenoceptors: Where, when, and how?
Okeke K, Angers S, Bouvier M, Michel MC.
Br J Pharmacol. 2019 Jul;176(14):2539-2558. Review.

58- ARGLU1 is a transcriptional coactivator and splicing regulator important for stress hormone signaling and development.
Magomedova L, Tiefenbach J, Zilberman E, Le Billan F, Voisin V, Saikali M, Boivin V, Robitaille M, Gueroussov S, Irimia M, Ray D, Patel R, Xu C, Jeyasuria P, Bader GD, Hughes TR, Morris QD, Scott MS, Krause H, Angers S, Blencowe BJ, Cummins CL.
Nucleic Acids Res. 2019 Apr 8;47(6):2856-2870.

59- Dual Regulatory Functions of SUFU and Targetome of GLI2 in SHH Subgroup Medulloblastoma.
Yin WC, Satkunendran T, Mo R, Morrissy S, Zhang X, Huang ES, Uusküla-Reimand L, Hou H, Son JE, Liu W, Liu YC, Zhang J, Parker J, Wang X, Farooq H, Selvadurai H, Chen X, Sau-Wai Ngan E, Cheng SY, Dirks PB, Angers S, Wilson MD, Taylor MD, Hui CC.
Dev Cell. 2019 Jan 28;48(2):167-183.e5. Epub 2018 Dec 13.

60- Three-Dimensional Nanostructured Architectures Enable Efficient Neural Differentiation of Mesenchymal Stem Cells via Mechanotransduction.
Poudineh M, Wang Z, Labib M, Ahmadi M, Zhang L, Das J, Ahmed S, Angers S, Kelley SO.
Nano Lett. 2018 Nov 14;18(11):7188-7193.

61- A synthetic anti-Frizzled antibody engineered for broadened specificity exhibits enhanced anti-tumor properties.
Pavlovic Z, Adams JJ, Blazer LL, Gakhal AK, Jarvik N, Steinhart Z, Robitaille M, Mascall K, Pan J, Angers S, Moffat J, Sidhu SS.
MAbs. 2018 Nov-Dec;10(8):1157-1167.

62- CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions.
Zimmermann M, Murina O, Reijns MAM, Agathanggelou A, Challis R, Tarnauskaitė Ž, Muir M, Fluteau A, Aregger M, McEwan A, Yuan W, Clarke M, Lambros MB, Paneesha S, Moss P, Chandrashekhar M, Angers S, Moffat J, Brunton VG, Hart T, de Bono J, Stankovic T, Jackson AP, Durocher D.
Nature. 2018 Jul;559(7713):285-289.

63- Wnt signaling in development and tissue homeostasis.
Steinhart Z, Angers S.
Development. 2018 Jun 8;145(11). pii: dev146589. Review.

64- A selective peptide inhibitor of Frizzled 7 receptors disrupts intestinal stem cells.
Nile AH, de Sousa E Melo F, Mukund S, Piskol R, Hansen S, Zhou L, Zhang Y, Fu Y, Gogol EB, Kömüves LG, Modrusan Z, Angers S, Franke Y, Koth C, Fairbrother WJ, Wang W, de Sauvage FJ, Hannoush RN.
Nat Chem Biol. 2018 Jun;14(6):582-590.

65- High-Density Proximity Mapping Reveals the Subcellular Organization of mRNA-Associated Granules and Bodies.
Youn JY, Dunham WH, Hong SJ, Knight JDR, Bashkurov M, Chen GI, Bagci H, Rathod B, MacLeod G, Eng SWM, Angers S, Morris Q, Fabian M, Côté JF, Gingras AC.
Mol Cell. 2018 Feb 1;69(3):517-532.e11.

66- ASCL1 Reorganizes Chromatin to Direct Neuronal Fate and Suppress Tumorigenicity of Glioblastoma Stem Cells.
Park NI, Guilhamon P, Desai K, McAdam RF, Langille E, O'Connor M, Lan X, Whetstone H, Coutinho FJ, Vanner RJ, Ling E, Prinos P, Lee L, Selvadurai H, Atwal G, Kushida M, Clarke ID,

Voisin V, Cusimano MD, Bernstein M, Das S, Bader G, Arrowsmith CH, Angers S, Huang X, Lupien M, Dirks PB.
Cell Stem Cell. 2017 Jul 11. pii: S1934-5909(17)30230-8.

67- Separating the Anti-Inflammatory and Diabetogenic Effects of Glucocorticoids through LXRβ Antagonism.
Patel R, Magomedova L, Tsai R, Angers S, Orellana A, Cummins CL.
Endocrinology. 2017 Apr 1;158(4):1034-1047.

68- Systematic protein-protein interaction mapping for clinically relevant human GPCRs.
Sokolina K, Kittanakom S, Snider J, Kotlyar M, Maurice P, Gandía J, Benleulmi-Chaachoua A, Tadagaki K, Oishi A, Wong V, Malty RH, Deineko V, Aoki H, Amin S, Yao Z, Morató X, Otasek D, Kobayashi H, Menendez J, Auerbach D, Angers S, Pržulj N, Bouvier M, Babu M, Ciruela F, Jockers R, Jurisica I, Stagljar I.
Mol Syst Biol. 2017 Mar 15;13(3):918.

69- Genome-wide CRISPR screens reveal a Wnt-FZD5 signaling circuit as a druggable vulnerability of RNF43-mutant pancreatic tumors
Steinhart Z, Pavlovic Z, Chandrashekhar M, Hart T, Wang X, Zhang X, Robitaille M, Jaksani S, Overmeer R, Boj SF, Adams J, Pan J, Clevers H, Sidhu S, Moffat J, Angers S
Nat Med. 2017 Jan;23(1):60-68.

70- Essential role of the Dishevelled DEP domain in a Wnt-dependent human-cell-based complementation assay.
Gammons MV, Rutherford TJ, Steinhart Z, Angers S, Bienz M.
J Cell Sci. 2016 Oct 15;129(20):3892-3902.

71- Identification of Novel Smoothened Ligands Using Structure-Based Docking.
Lacroix C, Fish I, Torosyan H, Parathaman P, Irwin JJ, Shoichet BK, Angers S.
PLoS One. 2016 Aug 4;11(8):e0160365. doi: 10.1371/journal.pone.0160365. eCollection 2016.

72- Dishevelled is a NEK2 kinase substrate controlling dynamics of centrosomal linker proteins.
Cervenka I, Valnohova J, Bernatik O, Harnos J, Radsetoulal M, Sedova K, Hanakova K, Potesil D, Sedlackova M, Salasova A, Steinhart Z, Angers S, Schulte G, Hampl A, Zdrahal Z, Bryja V.
Proc Natl Acad Sci U S A. 2016 Aug 16;113(33):9304-9.

73- Role of Spinophilin in Group I Metabotropic Glutamate Receptor Endocytosis, Signaling, and Synaptic Plasticity.
Di Sebastiano AR, Fahim S, Dunn HA, Walther C, Ribeiro FM, Cregan SP, Angers S, Schmid S, Ferguson SS.
J Biol Chem. 2016 Aug 19;291(34):17602-15.

74- PRICKLE1 Contributes to Cancer Cell Dissemination through Its Interaction with mTORC2.
Daulat AM, Bertucci F, Audebert S, Sergé A, Finetti P, Josselin E, Castellano R, Birnbaum D, Angers S, Borg JP.
Dev Cell. 2016 May 23;37(4):311-25.

75- Visualization of a short-range Wnt gradient in the intestinal stem-cell niche.
Farin HF, Jordens I, Mosa MH, Basak O, Korving J, Tauriello DV, de Punder K, Angers S, Peters PJ, Maurice MM, Clevers H.
Nature. 2016 Feb 18;530(7590):340-3.

76- SAPCD2 controls spindle orientation and asymmetric divisions by negatively regulating the Galphai-LGN-NuMA ternary complex.

Catherine Chiu, Carine Monat, Mélanie Robitaille, Marine Lacomme, Avais Daulat, Graham Macleod, Helen McNeil, Michel Cayouette, Stéphane Angers
Dev Cell. 2016 Jan 11;36(1):50-62.

77- YB-1 is elevated in medulloblastoma and drives proliferation in Sonic hedgehog-dependent cerebellar granule neuron progenitor cells and medulloblastoma cells.
Dey A, Robitaille M, Remke M, Maier C, Malhotra A, Gregorieff A, Wrana JL, Taylor MD, Angers S, Kenney AM. Oncogene. 2016 Jan 4.

78- High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities.
Hart T, Chandrashekhar M, Aregger M, Steinhart Z, Brown KR, MacLeod G, Mis M, Zimmermann M, Fradet-Turcotte A, Sun S, Mero P, Dirks P, Sidhu S, Roth FP, Rissland OS, Durocher D, Angers S, Moffat J.
Cell. 2015 Nov 25. pii: S0092-8674(15)01495-6.

79- A Par-1-Par-3-Centrosome Cell Polarity Pathway and Its Tuning for Isotropic Cell Adhesion.
Jiang T, McKinley RF, McGill MA, Angers S, Harris TJ.
Curr Biol. 2015 Oct 19;25(20):2701-8.

80- The Identification of Novel Protein-Protein Interactions in Liver that Affect Glucagon Receptor Activity.
Han J, Zhang M, Froese S, Dai FF, Robitaille M, Bhattacharjee A, Huang X, Jia W, Angers S, Wheeler MB, Wei L.
PLoS One. 2015 Jun 15;10(6):e0129226.

81- Gβ4γ1 as a modulator of M3 muscarinic receptor signalling and novel roles of Gβ1 subunits in the modulation of cellular signalling.
Khan SM, Min A, Gora S, Houranieh GM, Campden R, Robitaille M, Trieu P, Pétrin D, Jacobi AM, Behlke MA, Angers S, Hébert TE.
Cell Signal. 2015 Apr 23. pii: S0898-6568(15)00133-3.

82- BioID-based identification of SCF β-TrCP1/2 E3 ligase substrates.
Coyaud E, Mis M, Laurent EM, Dunham WH, Couzens AL, Robitaille M, Gingras AC, Angers S, Raught B.
Mol Cell Proteomics. 2015 Apr 21. pii: mcp.M114.045658.

83- Ca(2+)/Calmodulin-dependent protein Kinase II interacts with group I Metabotropic Glutamate and facilitates Receptor Endocytosis and ERK1/2 signaling: role of β-Amyloid.
Raka F, Di Sebastiano AR, Kulhawy SC, Ribeiro FM, Godin CM, Caetano FA, Angers S, Ferguson SS.
Mol Brain. 2015 Mar 26;8(1):21. doi: 10.1186/s13041-015-0111-4.

84- Stepping stone: a cytohesin adaptor for membrane cytoskeleton restraint in the syncytial Drosophila embryo.
Liu J, Lee DM, Yu CG, Angers S, Harris TJ.
Mol Biol Cell. 2014 Dec 24. pii: mbc.E14-11-1554. [Epub ahead of print]

85- The Pseudomonas syringae Type III Effector HopF2 Suppresses Arabidopsis Stomatal Immunity.
Hurley B, Lee D, Mott A, Wilton M, Liu J, Liu YC, Angers S, Coaker G, Guttman DS, Desveaux D.
PLoS One. 2014 Dec 11;9(12):e114921. doi: 10.1371/journal.pone.0114921. eCollection 2014.

86- The PPFIA1-PP2A protein complex promotes trafficking of Kif7 to the ciliary tip and Hedgehog signaling.
Liu YC, Couzens AL, Deshwar AR, B McBroom-Cerajewski LD, Zhang X, Puviindran V, Scott IC, Gingras AC, Hui CC, Angers S.

Sci Signal. 2014 Dec 9;7(355):ra117. doi: 10.1126/scisignal.2005608.

87- Ptch2 shares overlapping functions with Ptch1 in Smo regulation and limb development.
Zhulyn O, Nieuwenhuis E, Liu YC, Angers S, Hui CC.
Dev Biol. 2015 Jan 15;397(2):191-202. doi: 10.1016/j.ydbio.2014.10.023. Epub 2014 Nov 13.

88- Tandem affinity purification to identify cytosolic and nuclear gβγ-interacting proteins.
Campden R, Pétrin D, Robitaille M, Audet N, Gora S, Angers S, Hébert TE.
Methods Mol Biol. 2015;1234:161-84. doi: 10.1007/978-1-4939-1755-6_14.

89- Progesterone receptor membrane component 1 is a functional part of the GLP-1 receptor complex in pancreatic beta cells.
Zhang M, Robitaille M, Showalter AD, Huang X, Liu Y, Bhattacharjee A, Willard FS, Han J, Froese S, Wei L, Gaisano HY, Angers S, Sloop KW, Dai FF, Wheeler MB.
Mol Cell Proteomics. 2014 Jul 20. pii: mcp.M114.040196.

90- New insights in the regulation of Rab GTPases by G protein-coupled receptors.
Lachance V, Angers S, Parent JL.
Small GTPases. 2014;5:e29039. doi: 10.4161/sgtp.29039. Epub 2014 May 9.

91- Ubiquitylation and activation of a Rab GTPase is promoted by a β2AR-HACE1 complex.
Lachance, V., Degrandmaison, J., Marois, S., Robitaille, M., Génier, S., Nadeau, S., Angers, S., Parent, J.L. (2014)
J. Cell. Sci. 127(Pt 1):111-23

92- Novel, gel-free proteomics approach identifies RNF5 and JAMP as modulators of GPCR stability.
Roy, S.J., Glazkova, I., Fréchette, L., Iorio-Morin, C., Binda, C., Pétrin, D., Trieu, P., Robitaille, M., Angers, S., Hébert, T.E., Parent, J.L.
Mol. Endocrinol. 27(8):1245-66.

93- Evasion of p53 and G2/M checkpoints are characteristic of Hh-driven basal cell carcinoma.
Li, Z.J., Mack, S.C., Mak, T.H., Angers, S., Taylor, M.D., Hui, C.C.
Oncogene. (2013) [Jun 10. Epub ahead of print].

94- The human PDZome: a gateway to PSD95-Disc large-zonula occludens (PDZ)-mediated functions.
Belotti, E., Polanowska, J., Daulat, A.M., Audebert, S., Thomé, V., Lissitzky, J.C., Lembo, F., Blibek, K., Omi, S., Lenfant, N., Gangar, A., Montcouquiol, M., Santoni, M.J., Sebbagh, M., Aurrand-Lions, M., Angers, S., Kodjabachian, L., Reboul. J., Borg, J.P.
Mol. Cell. Proteomics. (2013) 12(9):2587-603.

95- A novel assay for measurement of membrane-protein surface expression using a β-lactamase.
Lam, V.M., Beerepoot, P., Angers, S., Salahpour, A.
Traffic. (2013) 14(7):778-84.

96- Ptk7 promotes non-canonical Wnt/PCP-mediated morphogenesis and inhibits Wnt/β-catenin-dependent cell fate decisions during vertebrate development.
Hayes M, Naito M, Daulat A, Angers S, Ciruna B.
Development. 2013 Apr;140(8):1807-18. doi: 10.1242/dev.090183.

97- Inhibition of tankyrases induces Axin stabilization and blocks Wnt signalling in breast cancer cells.
Bao R, Christova T, Song S, Angers S, Yan X, Attisano L.
PLoS One. 2012;7(11):e48670. doi: 10.1371/journal.pone.0048670. Epub 2012 Nov 7.

98- Radil controls neutrophil adhesion and motility through β2-integrin activation.
Liu L, Aerbajinai W, Ahmed SM, Rodgers GP, Angers S, Parent CA.

Mol Biol Cell. 2012 Dec;23(24):4751-65. doi: 10.1091/mbc.E12-05-0408. Epub 2012 Oct 24.

99- KIF14 negatively regulates Rap1a-Radil signaling during breast cancer progression.
Ahmed SM, Thériault BL, Uppalapati M, Chiu CW, Gallie BL, Sidhu SS, Angers S.
J Cell Biol. 2012 Dec 10;199(6):951-67. doi: 10.1083/jcb.201206051. Epub 2012 Dec 3.

100- A bacterial acetyltransferase destroys plant microtubule networks and blocks secretion.
Lee AH, Hurley B, Felsensteiner C, Yea C, Ckurshumova W, Bartetzko V, Wang PW, Quach V, Lewis JD, Liu YC, Börnke F, Angers S, Wilde A, Guttman DS, Desveaux D.
PLoS Pathog. 2012 Feb;8(2):e1002523. Epub 2012 Feb 2.

101- A protein complex of SCRIB, NOS1AP and VANGL1 regulates cell polarity and migration, and is associated with breast cancer progression.
Anastas JN, Biechele TL, Robitaille M, Muster J, Allison KH, Angers S, Moon RT.
Oncogene. 2011 Dec 19.

102- Mink1 regulates β-catenin-independent Wnt signaling via Prickle phosphorylation.
Daulat AM, Luu O, Sing A, Zhang L, Wrana JL, McNeill H, Winklbauer R, Angers S.
Mol Cell Biol. 2012 Jan;32(1):173-85. Epub 2011 Oct 28.

103- Calcium-sensing receptor modulates cell adhesion and migration via integrins.
Tharmalingam S, Daulat AM, Antflick JE, Ahmed SM, Nemeth EF, Angers S, Conigrave AD, Hampson DR.
J Biol Chem. 2011 Nov 25;286(47):40922-33. Epub 2011 Oct 3

104- Tandem affinity purification and identification of heterotrimeric g protein-associated proteins.
Ahmed SM, Daulat AM, Angers S.
Methods Mol Biol. 2011;756:357-70.

105- Gli proteins in development and disease.
Hui CC, Angers S.
Annu Rev Cell Dev Biol. 2011 Nov 10;27:513-37. Epub 2011 Jul 21. Review.

106- The Ubiquitin specific protease USP34 regulates Axin stability and Wnt/{beta}-catenin signaling.
Lui TT, Lacroix C, Ahmed SM, Goldenberg SJ, Leach CA, Daulat AM, Angers S.
Mol Cell Biol. 2011 Mar 7.

107- Oligomeric size of the M2 muscarinic receptor in live cells as determined by quantitative fluorescence resonance energy transfer (FRET).
Pisterzi LF, Jansma DB, Georgiou J, Woodside MJ, Chou JT, Angers S, Raicu V, Wells JW.
J Biol Chem. 2010 Mar 19.

108- G protein betagamma subunits regulate cell adhesion through Rap1a and its effector Radil.
Ahmed SM, Daulat AM, Meunier A, Angers S.
J Biol Chem. 2010 Jan 4.

109- YAP1 is amplified and up-regulated in hedgehog-associated medulloblastomas and mediates Sonic hedgehog-driven neural precursor proliferation.
Fernandez-L A, Northcott PA, Dalton J, Fraga C, Ellison D, Angers S, Taylor MD, Kenney AM.
Genes Dev. 2009 Dec 1;23(23):2729-41.

110- Glutamate transporter coupling to Na,K-ATPase.
Rose EM, Koo JC, Antflick JE, Ahmed SM, Angers S, Hampson DR.

J Neurosci. 2009 Jun 24;29(25):8143-55.

111- Proximal events in Wnt signal transduction.
Angers S, Moon RT
Nat Rev Mol Cell Biol. 2009 Jul;10(7):468-77. Review.

112- Modulation of the beta-catenin signaling pathway by the dishevelled-associated protein Hipk1.
Louie SH, Yang XY, Conrad WH, Muster J, Angers S, Moon RT, Cheyette BN.
PLoS ONE. 2009;4(2):e4310. Epub 2009 Feb 2.

113- Proteomic analyses of protein complexes in the Wnt pathway.
Angers S.
Methods Mol Biol. 2008;468:223-30.

114- New regulators of Wnt/beta-catenin signaling revealed by integrative molecular screening.
Major MB, Roberts BS, Berndt JD, Marine S, Anastas J, Chung N, Ferrer M, Yi X, Stoick-Cooper CL, von Haller PD, Kategaya L, Chien A, Angers S, MacCoss M, Cleary MA, Arthur WT, Moon RT.
Science Signal. 2008 Nov 11;1(45):ra12.

115- The tumor suppressor gene WTX, mutated in Wilms tumours, is a member of the beta-catenin destruction complex
Angers S.
Med Sci (Paris). 2007 Nov;23(11):1025-7.

116- Recovery of oligomers and cooperativity when monomers of the M2 muscarinic cholinergic receptor are reconstituted into phospholipid vesicles.
Ma AW, Redka DS, Pisterzi LF, Angers S, Wells JW.
Biochemistry. 2007 Jul 3;46(26):7907-27. Epub 2007 Jun 7

117- Wilms tumor suppressor WTX negatively regulates WNT/beta-catenin signaling.
Major MB, Camp ND, Berndt JD, Yi X, Goldenberg SJ, Hubbert C, Biechele TL, Gingras AC, Zheng N, Maccoss MJ, Angers S and Moon RT.
Science. 2007 May 18;316(5827):1043-6.

118- KLHL12/Cullin-3 is a new E3 ubiquitin ligase negatively regulating the Wnt pathway
Angers S.
Med Sci (Paris). 2007 Mar;23(3):243-4.

119- Molecular Architecture and Assembly of the DDB1-Cul4A Ubiquitin Ligase Machinery
Stephane Angers, Ti Li, Xianhua Yi, Michael J. MacCoss, Randall T. Moon and Ning Zheng
Nature. 2006 Oct 5;443(7111):590-3.

120- The KLHL12-Cullin-3 ubiquitin ligase negatively regulates Wnt β-catenin signaling by targeting Dishevelled for degradation.
Stephane Angers, Chris Thorpe, Travis Biechele, Seth Goldenberg, Ning Zheng, Michael Maccoss, Randall T. Moon
Nat Cell Biol. 2006 Apr;8(4):348-57. Epub 2006 Mar 19

121- An aplysia dopamine1-like receptor: molecular and functional characterization.
Barbas D, Zappulla JP, Angers S, Bouvier M, Mohamed HA, Byrne JH, Castsellucci VF, DesGroseillers L.
J Neurochem. 2006 Jan;96(2):414-27. Epub 2005 Nov 29.

122- Homodimerization of the beta 2-adrenergic receptor as a pre-requisite for cell surface targeting.
Salahpour A*, Angers S*, Mercier JF, Lagace M, Marullo S, Bouvier M.
J Biol Chem. 2004 Aug 6;279(32):33390-7. Epub 2004 May 20 * Co-first authorship

123- Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors.Azzi M, Charest PG, Angers S, Rousseau G, Kohout T, Bouvier M, Pineyro G.
Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11406-11. 2003 Sep 17.

124- The BRET2/arrestin assay in stable recombinant cells: a platform to screen for compounds that interact with G protein-coupled receptors (GPCRS).
Bertrand L, Parent S, Caron M, Legault M, Joly E, Angers S, Bouvier M, Brown M, Houle B, Menard L.
J Recept Signal Transduct Res. 2002 Feb-Nov;22(1-4):533-41.

125- Quantitative assessment of beta 1- and beta 2-adrenergic receptor homo- and heterodimerization by bioluminescence resonance energy transfer.
Mercier JF, Salahpour A, Angers S, Breit A, Bouvier M.
J Biol Chem. 2002 Nov 22;277(47):44925-31. Epub 2002 Sep 19.

126- Constitutive agonist-independent CCR5 oligomerization and antibody-mediated clustering occurring at physiological levels of receptors.
Issafras H, Angers S,Bulenger S, Blanpain C, Parmentier M, Labbe-Jullie C, Bouvier M, Marullo S
J Biol Chem. 2002 Sep 20;277(38):34666-73. Epub 2002 Jun 27.

127- Monitoring of ligand-independent dimerization and ligand-induced conformational changes of melatonin receptors in living cells by bioluminescence resonance energy transfer.
Ayoub MA, Couturier C, Lucas-Meunier E, Angers S, Fossier P, Bouvier M, Jockers R.
J Biol Chem. 2002 Jun 14;277(24):21522-8. Epub 2002 Apr 08.

128- Functional characterization of a novel serotonin receptor (5HTAP2) expressed in the CNS of Aplysia California.
Demian Barbas, Jacques P. Zapulla, Stephane Angers, Michel Bouvier, Vincent F. Castellucci, Luc DesGroseillers
J Neurochem. 2002 Jan;80(2):335-45.

129- Dimerization: An Emerging Concept for G protein Coupled Receptor Ontogeny and Function
Stephane Angers, Ali Salahpour, Michel Bouvier
Annu Rev Pharmacol Toxicol. 2002;42:409-35.

130- Biochemical and biophysical demonstration of GPCR oligomerization in mammalian cells.
Angers S, Salahpour A, Bouvier M.
Life Sci. 2001 Apr 6;68(19-20):2243-50.

131- Reply: beyond receptor dimerization
Angers S, Bouvier M.
Trends Pharmacol Sci. 2000 Sep;21(9):326.

132- Functional significance of oligomerization of G-protein-coupled receptors.Salahpour A, Angers S, Bouvier M.
Trends Endocrinol Metab. 2000 Jul;11(5):163-8. Review.

133- Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants.

Morello JP, Salahpour A, Laperrière A, Bernier V, Arthus MF, Lonergan M, Petäjä-Repo U, Angers S, Morin D, Bichet DG, Bouvier M.
J Clin Invest. 2000 Apr;105(7):887-95.

134- Detection of beta 2-adrenergic receptor dimerization in living cells using bioluminescence resonance energy transfer (BRET).
Angers S, Salahpour A, Joly E, Hilairet S, Chelsky D, Dennis M, Bouvier M.
Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3684-9**.**

135- Beta(2)-adrenergic receptor down-regulation. Evidence for a pathway that does not require endocytosis.
Jockers R, Angers S, Da Silva A, Benaroch P, Strosberg AD, Bouvier M, Marullo S.
J Biol Chem. 1999 Oct 8;274(41):28900-8.

SCIENCE OUTREACH

1. The GPCR podcast
   Ep. 92:
   Nov 3, 2022 https://podcasters.spotify.com/pod/show/dr-gpcr/episodes/92-with-Dr--Stephane-Angers-e1pite0

2. The Stem Cell Podcast
   Ep. 153: “Signal Transduction in Stem Cells and Cancer”
   October 15, 2019 https://stemcellpodcast.com/?s=stephane+angers

3. The Star
   Doctors’ Notes: Cancer treatment might be turning a corner
   Sun., Feb. 10, 2019.
   https://www.thestar.com/life/2019/02/10/doctors-notes-cancer-treatment-might-be-turning-a-corner.html

4. The Globe and Mail
   Canadian researchers hope new drugs possible for hardest-to-treat brain cancer
   April 16, 2019
   https://www.theglobeandmail.com/canada/british-columbia/article-canadian-researchers-hope-new-drugs-possible-for-hardest-to-treat/

5. L’Actualité
   Des chercheurs canadiens font avancer la lutte contre le glioblastoma
   https://lactualite.com/actualites/des-chercheurs-canadiens-font-avancer-la-lutte-contre-le-glioblastome/

6. Research2Reality
   Taking Apart the ‘Engine’ of Aggressive Brain Cancer
   September 2019
   https://research2reality.com/health-medicine/cancer/reverse-engineer-brain-cancer-cells-treatment-glioblastoma-multiforme/

GRANT SUPPORT AWARDED

1. Title: Precise modulation of the Wnt signalling pathway for endogenous tissue regeneration, cell therapy and tissue engineering
   Source: ORF-RE11

Funds awarded: $ 2.0 million ($790K to Angers) Dates: 2023-2027
P.I. S.Angers & Jeff Wrana

2. Title: Response of the Osteoporotic Skeleton to Mechanical Loading
   Source: NIH- R01AR047867
   Funds awarded: $ 3.457 million USD ($590K to Angers) Dates: 2023-2028
   P.I. M. Silva, collaborator S. Angers

3. Title: Investigation of a first-in-class Frizzled4/LRP5 agonist in retinal disease modelsSource: NIH- R01EY033316
   Funds awarded: $ 2.281 million USD ($567K to Angers) Dates: 2022-2027
   P.I. H. Junge, co-PI S. Angers

4. Title: Development of microfluidic enabled CRISPR-CAS9 functional genetic screening technologies for target discovery in cancer immunotherapy
   Source: NIH- 1R01CA260170-01
   Funds awarded: $ 1.06 million ($234K to Angers) Dates: 2021-2026
   P.I. S. Kelley, S. Angers, J. Moffat

5. Title: Assessing the efficacy of novel synthetic Wnt ligands to promote endothelial cell barrier function in diseases,
   Source: CIHR – Project - PJT-175160
   Funds awarded: $841,500 Dates: 2021-2026
   P.I. S. Angers

6. Title: Targeting Glioblastoma Heterogeneity through identification of subtype-specific genetic vulnerabilities
   Source: CIHR – Project - PJT-169054
   Funds awarded: $818,550 Dates: 2020-2025
   P.I. S. Angers

7. Title: Targeting Mesoderm Differentiation Bottlenecks for Regenerative Therapies
   Source: CFREF – Medicine by Design – Round 2
   Funds awarded: $3,500,000 (total) / $720,000 to Angers Dates 2019-2022
   P.I.: S. Kelley
   Co-Applicants: S.Angers, J. Moffat, S. Sidhu, A. Wheeler, B. Blencowe, A. Mcguigan, K. Pardee

8. Title: Epigenetic reorganization and differentiation of glioblastoma
   Source: CIHR - Canadian Epigenetics, Environment and Health Research Consortium
   Funds awarded: $1,500,000 (total) / $500,000 to Angers Dates 2018-2022
   P.I.: P.Dirks
   Co-Applicants: S.Angers, M. Lupien

9. Title: Brain Cancer TRI: Cellular and Genetic Heterogeneity as a Therapeutic Hurdle and Opportunity for Ontarians with Brain Cancer
   Source: OICR
   Funds awarded: $4,800,000 (total) / $236,460 to Angers Dates: 2017-2019
   P.I.s: P.Dirks, M. Taylor
   Co-Applicants: S.Angers, T. Pugh, S. Singh, X. Huang

10. Title: Targeting Wnt pathway in cancer with therapeutic antibodies.
    Source: Canadian Cancer Society Research Institute – IMPACT grant
    Funds awarded: $3,600,000 (total) / $974,976 to Angers Dates: 2017-2022
    P.I.s: S. Angers
    Co-Applicants: J. Moffat, S.Sidhu,

11. Title: Targeting Frizzled proteins in RNF43 mutant cancers.
    Source: Canadian Institute for Health Research, Project 1st Pilot
    Funds awarded: $1,005,320 (total) / $880,320 to Angers Dates: 2016-2021
    P.I.s: S. Angers, S. Sidhu
    Co-Applicants: J. Moffat, D. Hedley

12. Title: Systems level analysis of blood progenitor development from human pluripotent stem cells.
    Source: CFREF - Medicine by Design
    Funds awarded: $1,584,900 (total) / $300,000 to Angers Dates: 2016-2019
    P.I.s: J. Moffat
    Co-Applicants: S. Angers, G. Keller, B. Andrews, C. Boone

13. Title: Identification of GBM genetic wiring vulnerabilities.
    Source: Canadian Institute for Health Research, Targeting High Fatality Cancers - Innovation Grant
    Funds awarded: $100,000 Date: April 2016
    P.I.: S. Angers
    Co-Applicants: P. Dirks, J. Moffat

14. Title: Development and characterization of anti Fzd4 antibodies for the treatment of cancer.
    Source: Northern Biologics
    Funds awarded: $100,000 (direct costs) Date: 2015
    P.I.: S. Angers

15. Title: Pharmacological and Biochemical basis of Smoothened functional selectivity.
    Source: Canadian Institute for Health Research
    Funds awarded: $100,000 Date: July 2015
    P.I.: S. Angers
    Co-Applicant: B. Shoichet,

16. Title: A comprehensive antibody platform for targeting tumour heterogeneity
    Source: Ministry of Research and Innovation (MRI) – Ontario Research Fund-Research Excellence round 7 (ORF-RE7)
    Funds Awarded: $2,539,523 (total) / $260,000 (to Angers) Dates of Project: Apr 2015-Mar 2019
    P.I.s: S. Sidhu, B. Neel
    Co-Applicants: R. Rottapel, B. Wouters, S. Angers, C. O'Brien, J. Moffat
    The major goal of this project is to develop antibodies to fight cancer and advance biological knowledge.

17. Title: Confocal Microscopy Suite
    Source: Canadian Foundation for Innovation (CFI), Ontario Research Fund
    Funds awarded: $375,000 Sept 2014
    P.I.: S. Angers

18. Title: Role of the KIF14-Radil protein complex in breast cancer cells migration
    Source: Canadian Breast Cancer Foundation
    Funds awarded: $449,346 Dates: 05-2014 – 09-2017
    P.I.: S. Angers

19. Title: Wnt signalling circuitries in development and breast cancer
    Source: Canadian Institute for Health Research
    Funds awarded: $622,335 Dates: 10/2012 – 09/2017

P.I.: S. Angers

20. Title: Role of the KIF14-Radil protein complex in breast cancer cells migration
    Source: Canadian Breast Cancer Foundation
    Funds awarded: $413,028 Dates: 05-2011 – 05-2014
    P.I.: S. Angers

21. Title: Role of the P42.3 protein in mitotic spindle orientation
    Source: NSERC
    Funds awarded: $200,000 Dates: 05/2011 – 05/2017
    P.I.: S. Angers

22. Title: Synthetic antibody program: novel therapeutics and reagents
    Source: Genome Canada (GC) - Large-Scale Applied Research Project
    Funds Awarded: $4,849,413 (total) / $300,000 (to Angers) Dates of Project: Jul 2011-Dec 2014
    P.I.s: S. Sidhu, C. Boone
    Co-Applicants: J. Moffat, S. Angers, K. Bowman, I. Stagljar, B. Andrews, J. Dick, R. Rottapel, T. Pawson
    Large-scale collaborative grant for the identification of new antibody targets for cancer therapy and the development of antibodies against these targets.

23. Title: Molecular characterization of the key regulatory process controlling the Wnt pathway.
    Source: Canadian Institute for Health Research
    Funds awarded $627,065 Dates: 03/2007 – 03/2012
    P.I.: S. Angers

24. Title: Proximal signal transduction mechanisms of Wnt and Hedgehog receptors.
    Source: Canadian Cancer Research Society
    Funds awarded $120,000 Dates: 09/2007 – 09/2009
    P.I. S. Angers

25. CRC chair Tier II, Functional Architecture of Signal Transduction
    $1,000,000, Awarded 2007-2017
    P.I.: S. Angers

26. Title: Establishment of a proteomic platform at the University of Toronto
    Source: Canadian Foundation for Innovation, Ontario Research Fund
    Funds awarded: $434,360, 2007
    P.I.: S. Angers

27. Title: Pharmacological manipulation of β-catenin protein stability for cancer therapy.
    Source: Connaught grant, University of Toronto
    Funds awarded: 30,000$, March 2007
    P.I.: S. Angers

AWARDS

1- 2013 Professor of the year award, Leslie Dan Faculty of Pharmacy

2- 2009 Canadian Society for Pharmaceutical Sciences, GSK Early Career Award

3- 2008 Early Researcher Award, Ministry of Research and Innovation Ontario

4- 2007-2017 Canada Research Chair Tier II – Functional Architecture of Signal Transduction

5- 2000 Bernard Belleau Award- Awarded by L'Association Canadienne Francaise pour l'Avancement des Sciences (ACFAS)

INVITED SEMINARS

1- 2025 Wnt Signaling Conference Gordon Research Conference, June 22-27, 2025, Bates College, Maine
"Manipulating Cell Fate with Frizzled Agonists" Invited by Ken Cadigan

2- 23rd GPCR retreat, May 15-17 2025, Bromont, Qc
"A New Lens on Wnt Receptor Activation Drives a First-in-Class Therapy for Retinal Diseases".

3- Duke-NUS, Singapore, May 8 2025
"Restoring tissue homeostasis with tailored control of Wnt signaling activity" Invited by Nick Tolwinsky

4- ASIP annual meeting, Portland Oregon, April 2025
"Manipulating Wnt signaling with antibody agonists to restore tissue homeostasis" Invited by Paul Monga

5- Department of Immunology, University of Toronto, January 6 2025
"Restoring tissue homeostasis with tailored control of Wnt signaling activity". Invited by Alberto Martin

6- Wnt Meeting 2024, Heidelberg Sept 25-27 2024
"Restoring tissue homeostasis with tailored control of Wnt signaling activity." Invited by Michael Boutros

7- 18th Annual Bellairs meeting, The cell and systems biology of disease, Barbados Feb 2024
"A drug discovery journey in academia"

8- Two decades of research at IRIC Symposium, Montreal, Oct 19-20 2023
Promoting tissue regeneration through modulation of Wnt signalling. Invited by Michel Bouvier

9- Advances in Biomedical Research V, Split Croatia, September 15th -19th, 2023.
Promoting tissue regeneration through modulation of Wnt signalling. Invited by Igor Stagljar

10- Wnt 2022, EMBO Workshop, Awaji island, Hyogo, Japan, November 2022
"Manipulating stem cell fate using selective Frizzled agonists"

11- NIH, National Cancer Institute, Neuro-oncology branch, Sept 14, 2022
"Charting genetic vulnerabilities of brain tumours." Invited by Chunzhang Zhang

12- 16th Annual Bellairs meeting - The Cell and Systems Biology of Disease, Barbados April 2022
Treatment of retinopathies and Parkinson Disease with Frizzled antibody agonists

13- PRiME-HUJI Mini-Symposium – Feb 24 2021 – Virtual Talk
Promoting stem cell activity using proximity-inducing antibodies for tissue regeneration

14- Proxidrugs Network, University of Frankfurt – September 2020 – Virtual talk
Manipulating developmental pathways using proximity-inducing antibody modalities. Invited by Ivan Dikic

15- Cancer Research Center of Laval University (Québec, Canada). Plenary speaker annual Journée Scientifique des Étudiants (JSE) August 2020
"Therapeutic targeting of Wnt signaling in Cancer and tissue regeneration"

16- Dept of Pharmacology & Therapeutics, Faculty of Medicine, McGill University, May 2020
"Targeting of Stem Cell Developmental Signals for Cancer Therapy and Regenerative Medicine" Invited by JF Trempe

17- Wnt 2020, EMBO Workshop, Awaji island, Hyogo, Japan, September 2020
"Manipulating stem cell fate using selective Frizzled agonists" (postponed Covid Pandemic)

18- Van Andel Institute Seminar Series, Grand Rapids Michigan, June 2020
"Therapeutic targeting of Wnt signaling in Cancer and tissue regeneration" Invited by Bart Williams (postponed Covid Pandemic)

19- Insitro Therapeutics, April 2020
"Identification of therapeutic targets in Glioblastoma using functional genomics" Invited by Ajamete Kaykas (postponed Covid Pandemic)

20- Genentech, April 2020
"Therapeutic targeting of Wnt signaling in Cancer and tissue regeneration" Invited by Vishva Dixit (postponed Covid Pandemic)

21- Institute of Research in Immunology and Cancer (IRIC) Distinguished Scientists Lecture, Jan 2020
"Therapeutic targeting of Wnt signaling in Cancer and tissue regeneration" Invited by Michel Bouvier

22- SunnyBrook Research Institute, January 2020
"Therapeutic targeting of the Wnt pathway in cancer and tissue regeneration", Invited by Isabelle Aubert

23- 20th Annual GPCR Great Lake Retreat, Bromont, Quebec, September 2019
"Targeting Wnt signaling in Cancer and Regenerative Medicine"

24- Cincinnati Children's, Cincinnati, April 24th, 2019
"Targeting Wnt signaling in Cancer and Regenerative Medicine" Invited by Josh Waxman

25- UNC Lineberger Comprehensive Cancer, North Caroline, April 17th, 2019
"Targeting Wnt signaling in Cancer and Regenerative Medicine" Invited by Ben Major

26- Montreal Neurological Institute, March 21, 2019
"Targeting Wnt Signaling in Cancer and Tissue Regeneration" Invited by Ted Fon

27- 15th Annual International Bellairs Research Workshop on "The Cell and Systems Biology Of Disease: Concepts and Challenges. January 2019
"Wnt signalling in cancer and tissue regeneration" Invited by Drs. Heidi McBride, Morag Park and Anne-Claude Gingras

28- Emerging Data on the Role of Wnt Biology in Cancer, Banbury Center of Cold Spring Harbor,
"Charting Wnt signaling networks in normal and cancer cells using CRISPR functional genomic screens" October 7-10, 2018, Invited by Hans Clevers

29- Europeen Wnt meeting, Heidelberg, Germany, Sept 9-14 2018
“Identification of synthetic lethal interactions underlying cancer mutations within the Wnt signaling pathway” , Invited by Michael Boutros

30- Repare Therapeutics, Montreal, June 2018
“Leveraging CRISPR-Cas9 screens for identification of cancer vulnerabilities and new therapeutics.”

31- Signalisation Quebec 2018, Bécancourt, Qc June 6-8th 2018
“Identification des gènes essentiels pour les cellules souches du glioblastome."

32- "XXIVe Journée scientifique des programmes de biologie moléculaire de l'Université de Montréal" May 18th, 2018
Plenary lecture: Drugging the Wnt pathway in Cancer and regenerative medicine.

33- Experimental Biology 2018 in San Diego, CA, April 21-25, 2018.
Genome-Wide CRISPR Screens Reveal Wnt-Frizzled Functional Selectivity in Pancreatic Cancer
Julius Axelrod Symposium: The Pluridimensionality of G Protein-Coupled Receptor (GPCR) Signaling, Invited by Michel Bouvier

34- 11th Conference on Signalling in Normal and Cancer Cells, Banff, AB, April 15-19, 2018
“Leveraging Parallel CRISPR-Cas9 screens for identification of new therapeutic targets in high-fatality cancers”, Invited by Jean-Francois Cote

35- DNA Damage Response Therapeutics Summit 2018, Boston, January 30-Feb 1st 2018
Leveraging CRISPR-Cas9 screens for identification of PDAC and GBM cancer vulnerabilities and new therapeutics.

36- University of Toronto Mississauga, Department of Chemistry and Physical Sciences, November 22, 2017
Leveraging CRISPR-Cas9 screens for identification of cancer vulnerabilities and new therapeutics., Invited by Scott Prosser

37- GDR 3545 6th annual meeting “GPCR from physiology to drugs”, Université Paris Descartes, Paris, France, Nov 9th 2017
Wnt-FZD5 signalling circuit as a druggable vulnerability of RNF43-mutant pancreatic tumours.

38- 2017 NextGen Genomics, Biology, Bioinformatics and Technologies (NGBT) Conference, October 2 - 4, 2017 Bhubaneswar, India.
Leveraging genome-wide CRISPR-Cas9 screens and synthetic lethal interactions for novel cancer therapeutics.

39- Gordon Research Conference, Wnt Signaling, August 5-10, 2017, Stowe, VT
Identification of FZD5 as a genetic vulnerability in RNF43 mutant cancers.

40- Meakins-Christie Laboratories, Mcgill University, May 1st 2017
Leveraging genome-wide CRISPR screens and synthetic lethal interactions for novel cancer therapeutics, Invited by Simon Rousseau

41- Institut Cochin, Paris, April 26 2017
Identification of new therapeutic opportunities in cancer using CRISPR screens.
Invited by Mark Scott

42- Université de Montréal, Department of Anatomy and Pathology, Annual Research Day, April 2017
"Identification des vulnérabilité génétiques dans le cancer au moyen de cribles CRISPR pour le développement de nouvelles thérapies", Invited by Jean-Claude Labbé and Phillipe Roux

43- AACR: Opportunities and Challenges of Exploiting Synthetic Lethality in Cancer, San Diego, Ca, January 2017
Leveraging genome-wide CRISPR screens and synthetic lethal interactions for novel cancer therapeutics, Invited by René Bernards

44- Terry Fox, Ontario Node Research Symposium – Toronto, Ontario, December 2016
Targeting cancer vulnerabilities uncovered using genome-wide CRISPR-Cas9 screens.
Invited by Dr. Sheila Sing

45- World Life Science Conference, Beijing, China, November 2016
Identification of new therapeutic opportunities in cancer using CRISPR screens.
Invited by C-c Hui

46- Wnt meeting conference 2016 – EMBO, Brno, Czech rep. Sept 14-17, 2016
CRISPR screens reveal a Wnt-FZD5 signaling circuit as a therapeutic opportunity in pancreatic cancer.

47- Signalisation Québec, Becancourt, Qc, June 2016
Identification de vulnérabilités génetiques dans les cellules cancéreuses au moyen de cribles CRISPR : nouvelles cibles thérapeutiques., Invited by Dr. Marie-Josée Boucher

48- Princess Margaret Hospital Research Seminar, May 5th 2016
Identification of cancer vulnerabilities using genome wide CRISPR-Cas9 screens.
Invited by Dr. Rob Rottapel

49- American Association for Cancer Research (AACR), Annual Meeting, Workshop on Functional Screening using CRISPR-Cas9, New Orleans, April 15-20 2016
Identification of new therapeutic opportunities in cancer using CRISPR screens.
Invited by Feng Zhang

50- Department of Laboratory Medicine and Pathology, Univ. of Toronto, Annual Research Day, April 13th, 2016
Finding new cancer therapeutic strategies using genome-wide CRISPR screens.
Invited by the Graduate Students

51- 12th Annual Bellairs Research Workshop, Cell Biology of Disease, Barbados, January 2016
Deciphering Wnt signalling and drug sensitivity using whole genome CRISPR-Cas9 screens
Invited by Dr. Peter McPherson

52- Developmental Biology and Cancer, American Association For Cancer Research (AACR), Nov 30 – Dec 3 2015
"Inhibiting the Wnt pathway with selective anti-Frizzled synthetic antibodies"
Invited by Hans Clevers

53- HUPO World Congress on Human Proteome Organization, Vancouver, Sept 27-30 2015
Study of Cancer Cell Signalling and Drug Sensitivity using CRISPR-Cas9 sgRNA libraries.

54- 2015 Canadian Society for Pharmaceutical Sciences (CSPS) Annual conference, May 26-28 2015
"Deciphering growth factor signalling mechanisms in Cancer using functional genomics and proteomics."

55- Department of Cell and Systems Biology, Graduate Research day, Plenary speaker, May 1st 2015. "Deciphering cell signalling mechanisms in development and cancer using functional OMICS approaches." Invited by the Graduate Students.

56- Graduate Medical School, National University Singapore, October 2014
The PPFIA1-PP2A protein complex promotes Kif7 ciliary tip trafficking and Hedgehog signaling. Invited by Dr. David Virshup

57- EMBO Workshop on Wnt signalling, Broome, Australia, October 2014
Systematic targeting of Wnt receptors using synthetic antibodies
Invited by Dr. Elizabeth Vincan

58- Signalisation Québec, Becancourt, Qc, June 2014
Régulation du transport intraflagellaire lors de l'activation de la voie Hedgehog.
Invited by Dr. Darren Richard

59- Cell Polarity Signaling, Gordon Research Conference, Waltham, MA, June 2014
SAPCD2 Negatively Regulates the Gai-LGN-NuMA Complex During Spindle Positioning and Asymmetric Cell Division, Invited by Dr. Ian Macara

60- Institut de Recherche en Immunologie et Cancer (IRIC), February 2013
Understanding the Many Roles of G protein Signalling in Cancer using Functional Proteomics
Invited by Dr. Pierre Thibeault

61- GPCR Great Lake Retreat, London, Ontario October 2012
Role of the Gbg-Rap1a-Radil complex in breast cancer, Invited by Dr. Steve Fergusson

62- Department of Biochemistry, McGill University, April 2012
Wnt-PCP signalling in development and disease,
Invited by Drs. Thomas Duchaine and Jose Teodoro

63- The Biotechnology Center of the Technische Universität Dresden, Germany, December 2011
Wnt-PCP signalling in development and disease, Invited by Dr. Gilbert Weidinger

64- Department of Biology at McMaster University, Hamilton, November 2011
Wnt-PCP signalling in development and disease., Invited by the graduate students

65- International Wnt 2011 meeting, UCLA, Los Angeles, June 2011
Mink1 regulates the trafficking and cellular localization of Prickle during β-catenin-independent Wnt signaling., Invited by Drs. Tim Lane and Marian Waterman

66- Department of Pharmacology, University of Rochester, NY, USA, April 2011
The Gβγ-Radil-Rap1a complex in cell adhesion, migration and cancer.
Invited by Dr. Gregory Tall

67- Children's Health Research Institute, London, Ontario, Canada, April 2011
Beta-catenin Independent Wnt Signalling in Development and Disease.
Invited by Dr. Greg Kelley

68- 9th Conference on Signalling in Normal and Cancer Cells, Banff, Alberta, Canada, March 2011
A targeted siRNA screen reveals a role for the Frizzled-7 Wnt receptor in breast cancer cells migration., Invited by Dr. Andre Veillette

69- Department of Pharmacology, University of Toronto, December 2010

Beta-catenin Independent Wnt Signalling in Development and Disease.
Invited by David Riddick

70- Signalisation Québec 2010, June 2010
Étude de la logique moléculaire de la voie Wnt par protéomique fonctionelle.
Invited by Dr. Marc Therrien

71- Centre de recherche de L'Hôtel-Dieu de Québec/CHUQ, May 2010
Étude de la logique moléculaire de la voie Wnt par protéomique fonctionelle.
Invited by Dr. Josée Lavoie

72- Ottawa Research Institute, Ontario, Canada, April 2010
Study of Wnt signalling using functional proteomics., Invited by Dr. Lynn A. Megeney

73- University of Toronto, LMP seminar series, November 2009
Application of functional proteomics to cellular signalling., Invited by Dr. Maria Rozakis

74- Ubiquitin Drugs Discovery & Diagnostics, October 2009
USP34 controls the nuclear localization of Axin to positively regulate Wnt/b-catenin signaling.
Invited by Dr. Seth Goldenberg, Progenra Inc.

75- University of Toronto, Department of Physiology, September 2009
Investigating G Protein Signalling using functional proteomics, Invited by Dr. Sebastien Boltz

76- Robarts Institute, April 2009,
Functional proteomics of G protein signalling, Invited by Dr. Stephen Ferguson

77- Program in Cell Biology, Sick Kids, Toronto, February 2009
Characterization of Novel Actors in the Wnt Signalling Pathway Using Functional Proteomics
Invited by Dr. William Trimble

78- Molecular Pharmacology of GPCRs, Sydney Australia, November 2008
Investigating GPCR signal transduction using functional proteomics
Invited by Dr. Patrick Sexton

79- GPCR Great Lake Retreat, Bromont Quebec, October 2008
Investigating GPCR signal transduction using functional proteomics
Invited by Dr. Stephane Laporte

80- Citywide Endocrine Rounds, Mount Sinai Hospital, Toronto, March 2008
Defining the molecular logic of the Wnt signalling pathway using functional proteomics.
Invited by Dr. Susan George

81- Department of Pharmacology, Mcgill University, November 2007
Defining the molecular logic of the Wnt signalling pathway using functional proteomics.
Invited by Dr. Terry Hebert

82- Department of Cell and Systems Biology, University of Toronto, October 2007
Characterization of Novel Actors in the Wnt Signalling Pathway Using Functional Proteomics
Invited by Dr. Darrell Deveaux

83- Department of Biochemistry, University of Toronto, June 2007
Targeted proteomic analyzes of the Wnt signalling pathway, Invited by Dr. Reinhart Reithmeir

84- Department of Biochemistry, Queens University, April 2007
Targeted proteomic analyzes of the Wnt signalling pathway, Invited by Dr. Glen Jones

85- CHUM & Department Pathology and Cell Biology, Université de Montréal, May 2006
Études protéomiques de la voie de signalisation Wnt.
Invited by Drs. Guy Rouleau & Pierre Drapeau

86- Leslie Dan Faculty of Pharmacy, University of Toronto, May 2006
Molecular dissection of the Wnt pathway using targeted proteomics
Invited by Dr. Wayne Hindmarsh

87- Stem Cells Research Institute, McMaster University, April 2006
Molecular dissection of the Wnt pathway using targeted proteomics
Invited by Dr. Mick Bathia

PEER REVIEW

2006-Present Ad hoc reviewer for Genes & Development, Molecular and Cellular Biology, Faseb Journal, Journal of Cell Biology, Genetics, Molecular Genetics and Genomics, PNAS, Biochemistry, American Journal of Cell Physiology, Oncogene, Biology Open, Journal of Neurochem, Journal of Neuroinflammation, Molecular Cell, Nature Medicine, Open Biology, Development, Developmental Cell, Nature, Elife, Cancer Discovery, Science Signaling, Journal of Clinical Investigation, Nature Communication, EMBOJ, Scence Advance, Embo Molecular Medicine, Science

CONFERENCE ORGANIZER

2023 Gordon Research Conference – Wnt Signaling - Chair

August 2019 Gordon Research Conference - Wnt Signaling Networks in Development, Disease and Regeneration – Mount Snow, VT, USA Vice Chair

October 2015 16th Great Lakes GPCR Retreat – Hockley Valley, Ontario, Canada, Co-organizer

October 2010 11th Great Lakes GPCR Retreat - King City, Ontario. Canada, Co-organizer

PEER REVIEW COMMITTEES

2023 Canadian Cancer Research Society, CCS Challenge Grants – C4a - Therapeutics panel

2021 Connaught Awards, University of Toronto

2021 Project grant, Canadian Institute of Health Research, Molecular and Cellular Biology of Cancer Panel.

2018 IMPACT grant program reviewer, Canadian Cancer Society Research Institute

2018 Scientific Officer, CIHR, Cancer Biology & Therapeutics C2 Committee

2017 IMPACT grant program reviewer, Canadian Cancer Society Research Institute

2017 Scientific Officer for Cancer Therapeutics cluster, Canadian Institute of Health Research Program Grant Fall competition

2016	Reviewer Cancer Research Society, Panel A
2015-	Member of the College of Reviewers, Canadian Institute of Health Research
2015	Stg1 reviewer, Foundation grant, Canadian Institute of Health Research
2014	Stg1 reviewer, Foundation grant, Canadian Institute of Health Research
2014-2015	Invited Member, Canadian Institute of Health Research, Molecular and Cellular Biology of Cancer Panel.
2009-2013	Full member, Canadian Institute of Health Research, Molecular and Cellular Biology of Cancer Panel.
2008	Invited Member, Canadian Institute of Health Research, Molecular and Cellular Biology of Cancer Panel.
2007	Invited Member, Canadian Institute of Health Research, Pharmacology and Toxicology panel

TRAINEES

M.Sc.	**Tenure**	**Present position**
Tony Lui	01/07 – 10/09	MD, NUH Singapore
Meng Zhang	09/16 – 01/20	Trindent Consulting
Elli Kubarakos	09/16 – 09/20	Research Associate at BlueRock Therapeutics
Sophia Zelko	09/20 – 08/23	
Sarah Moldaver	09/20 –	
Missy Kim	09/24 –	

Ph.D

Syed Mukhtar Ahmed	07/07 – 12/12	Research Asst. Prof., Vanderbilt University
Celine Lacroix	11/07 – 07/16	Sales Representative at Medtronic
Yulu Cherry Liu	01/09 – 08/15	Asst. Prof., Dept of Biology, Hood College
Catherine Chiu	09/11 – 01/18	Medical Information Manager at Amgen
Nishani Rajakulendran	09/12 – 04/19	R&D Associate at Edesa Biotech
Monika Mis	09/12 – 04/19	Scientist, Genentech
Zachary Steinhart	01/13 – 04/19	Post Doctoral Fellow, UCSF
Milena Kosic	01/16 – 10/23	Principal Scientist, CCRM, Toronto
Siobhan O'Brien	01/18 – 12/22	Post-Doctoral Fellow, Fred Hutch, Seattle
De Hua Yang	09/18 – 05/24	
Fatemeh Molaei	09/19 –	
Althea Xu	09/20 –	
Lillian Kim	09/20 –	
Frank Oteng	01/22 –	
Qiyu Yan	09/23 –	
Byuri Sim	01/24 –	

Post-doctoral Fellow

Dr. Avais Daulat	04/08 – 01/12	Technology specialist, Institut Paoli-Calmettes
Dr. Mélanie Robitaille	07/09 – 10/14	Research Professor, University of Queensland
Dr. Josiah Obiero	01/12 – 03/13	
Dr. Graham Macleod	09/13 – 07/17	Senior Research Associate

Dr. Keith Mascall	09/15 – 12/17	QA Complaint Manager at Sandoz
Dr. Moloud Ahmadi	09/16 – 04/20	Scientist at CCRM, Cell and Gene Therapy
Dr. Rony Chidiac	04/18 – 10/23	Assistant Professor, Université de Sherbooke
Dr. Graham Macleod	07/17 – 09/20	Senior Research Associate, Angers Lab
Dr. Javier Koh	02/20 – 04/21	Scientist, Singapore
Dr. Maira Pedroso De Almeida	11/20 –	
Dr. Pierre Thibeault	01/21 –	
Dr. Lucie Wolf	05/22 –	

Research Associate

Dr. Graham Macleod	09/20 –	
Dr. Nancy Chang	07/17 – 07/18	Clinical Res Coord., Hospital for Sick Children
Dr. Sophia Wang	02/18 – 12/18	RA, Univ. of Texas Southwestern

Research Technician

Nathalie Lavine	2006- 2008	RA, University of Manitoba
Andrew Chang	2008- 2010	PharmD Candidate, University of Waterloo
Sichun Lin	2016-	
Yun Hye Kim	2018-2024	